Importantly, the clinical benefits of blocking the PD-1/PD-L1 immune checkpoint occurred across various tumor types, including melanomas, colorectal, and non-small cell lung cancers (NSCLCs), highlighting the likelihood that increased mutational burden was the common denominator of ICB efficacy between these tumors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.